Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

162 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT03793179
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-26

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-26

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT03793179 (opens in a new tab) (Clinical-trial registry) NCT03793179 Primary source NCT03793179
ClinicalTrials.gov — NCT03793179. NCT03793179.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT06348199
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Non-small Cell Lung Cancer Stage IV who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-26

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-26

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06348199 (opens in a new tab) (Clinical-trial registry) NCT06348199 Primary source NCT06348199
ClinicalTrials.gov — NCT06348199. NCT06348199.

Eligibility varies — review trial criteria.

Trial Watch: Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT07149649
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Metastatic NSCLC - Non-Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-24

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-24

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07149649 (opens in a new tab) (Clinical-trial registry) NCT07149649 Primary source NCT07149649
ClinicalTrials.gov — NCT07149649. NCT07149649.

Eligibility varies — review trial criteria.

Trial Watch: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

InvestigationalRegistered later-phase trial

Cancer type: Bladder Cancer
Trial identifier: NCT03711032
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with High-risk Non-muscle Invasive Bladder Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-24

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-24

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT03711032 (opens in a new tab) (Clinical-trial registry) NCT03711032 Primary source NCT03711032
ClinicalTrials.gov — NCT03711032. NCT03711032.

Eligibility varies — review trial criteria.

Trial Watch: A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

InvestigationalRegistered later-phase trial

Cancer type: Breast Cancer
Trial identifier: NCT07060807
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Breast Neoplasms who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-24

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-24

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07060807 (opens in a new tab) (Clinical-trial registry) NCT07060807 Primary source NCT07060807
ClinicalTrials.gov — NCT07060807. NCT07060807.

Eligibility varies — review trial criteria.

Trial Watch: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

InvestigationalRegistered later-phase trial

Cancer type: Breast Cancer
Trial identifier: NCT01674140
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Breast Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-24

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-24

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT01674140 (opens in a new tab) (Clinical-trial registry) NCT01674140 Primary source NCT01674140
ClinicalTrials.gov — NCT01674140. NCT01674140.

Eligibility varies — review trial criteria.

Trial Watch: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

InvestigationalRegistered later-phase trial

Cancer type: Pancreatic Cancer
Trial identifier: NCT06943755
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-24

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-24

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06943755 (opens in a new tab) (Clinical-trial registry) NCT06943755 Primary source NCT06943755
ClinicalTrials.gov — NCT06943755. NCT06943755.

Eligibility varies — review trial criteria.

Trial Watch: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

InvestigationalRegistered later-phase trial

Cancer type: Bladder Cancer
Trial identifier: NCT07097142
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07097142 (opens in a new tab) (Clinical-trial registry) NCT07097142 Primary source NCT07097142
ClinicalTrials.gov — NCT07097142. NCT07097142.

Eligibility varies — review trial criteria.

Trial Watch: A Study of Acalabrutinib vs Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

InvestigationalRegistered later-phase trial

Cancer type: Leukemia
Trial identifier: NCT02970318
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Chronic Lymphocytic Leukemia who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT02970318 (opens in a new tab) (Clinical-trial registry) NCT02970318 Primary source NCT02970318
ClinicalTrials.gov — NCT02970318. NCT02970318.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT06561386
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Non-small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06561386 (opens in a new tab) (Clinical-trial registry) NCT06561386 Primary source NCT06561386
ClinicalTrials.gov — NCT06561386. NCT06561386.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.